Henry Schein Inc

Henry Schein trades at a 21.3x P/E despite RSI of 39.8, signaling neither overbought nor oversold conditions—a curious disconnect. The 6.82% short interest is modest, suggesting limited squeeze potential, while the stock sits below its 52-week high, indicating room for appreciation if fundamentals hold. For a wholesale medical-supplies distributor in the consumer cyclical space, this valuation sits at an inflection point: expensive enough to price in recovery optimism, yet the depressed RSI and distance from yearly peaks hint at lingering skepticism. The setup appears neither compelling nor deeply discounted, more a wait-and-see posture for confirmation of demand sustainability in healthcare spending.